This month's top tech news stories
CrestOptics
Innovative Collaboration
CrestOptics, a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy and diagnostic applications, has been selected by Akoya Biosciences, to jointly develop new spatial biology and spatial phenotyping applications.
It has been invited to the partnership among other leading companies in the field of imaging and diagnostics to support Akoya’s Imaging Innovators Network.
Renato Giacobbo Scavo, CEO of CrestOptics, said: “We are focused on developing versatile systems for a variety of applications to support researchers in the cell biology and imaging space, and are excited to be a part of this innovative collaboration to expand imaging capabilities for life sciences.”
Liver disease
CN Bio, which designs and manufactures single and multi-organ microphysiological systems (MPS), has announced that King’s College London has adopted its technology to investigate chronic liver disease.
It selected the PhysioMimixMulti-Organ MPS system to create a unique human-relevant liver-intestinal model for characterising and manipulating host–microbial interactions, to support improved outcomes in cirrhosis.
Avacta Group
Lateral flow test
Avacta Group has announced that a study shows its AffiDX antigen lateral flow test (LFT) detects the Delta variant of the SARS-CoV-2 virus in clinical samples.
In the small study it outperformed two LFTs that are commercially available in Europe. The clinical data for Avacta’s AffiDX SARS-CoV-2 antigen LFT demonstrated 100% sensitivity for identifying infectious individuals with viral loads measured by PCR of Ct<27, which is considered infectious.
Image credit | CrestOptics |CN-Bio